General contact

Main switchboard

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST


Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999


Investor Relations

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Stay up-to-date

Stay connected to the latest news and information from Novartis.

E-mail alerts

If you wish to receive media releases from Novartis, please provide the following information:

Please fill in all mandatory fields marked with an asterisk (*)

Personal information
Company Information


Personal data marked with an asterisk (*) are essential to provide our service to you and must be filled out.

By submitting this data profile form, you consent to Novartis AG collecting and processing your personal data for Novartis internal use, in accordance with our privacy policy, and by protected technical means.

Novartis RSS feeds

Please select an RSS feed from the appropriate category below.

By language:

English Fran├žais Deutsch

By keyword:

Cardiovascular Diabetes Neuroscience
Infectious Diseases Oncology Novartis Consumer Health
Respiratory Vaccines Sandoz
Alcon and Eye care

Novartis Corporate Responsibility e-newsletter

Subscribe here to receive Novartis Corporate Responsibility News, a quarterly
e-newsletter that will keep you updated on our CR programs and initiatives.

Social media

Subscribe to the Novartis YouTube channel

Connect with Novartis on Linkedin

View Novartis images on Flickr

Follow Novartis on Pinterest

Follow Novartis on Instagram

Follow Novartis on Flipboard